Click here to start

Author: Dr Andrew Wright

Table of contents

CFS/ME A REVIEW/UPDATE ON THE ‘TERRIBLE TRIO’
Slide 2
CFS/ME IN THE UK
KEY POINTS
Slide 5
HISTORICAL DEFINITIONS
Slide 7
BENIGN MYALGIC ENCEPHALOMYELITIS Goodwin CS. Lancet Jan 3rd 1981, p 37
Slide 9
OXFORD CRITERIA 1991
Slide 11
CANADIAN CONSENSUS 2003
Slide 13
Slide 14
Slide 15
HMPAO SPECT and T2 weighted MRI in a patient with CFS/ME
Slide 17
Slide 18
Slide 19
Slide 20
Neutrophil Apoptosis Results
Free Radicals: Precipitating factors
Free radicals
Slide 24
Slide 25
Slide 26
Whole-genome DNA Microarray Analysis of Gene Expression in CFS
Iterative Group Analysis of Significantly Differentially Expressed Genes/Pathways conclusions
Iterative Group Analysis of Significantly Differentially Expressed Genes/Pathways Conclusions
Slide 30
The ‘Terrible Trio’
MICROBES
Slide 33
Slide 34
Slide 35
Slide 36
Slide 37
Spirochaetal Life Cycle Of Borrelia Anserina In Argus
Slide 39
40
Slide41
Importance Of 1,25 D And Angiotensin 2 Receptors in Chronic Inflammatory Diseases
Angiotensin II Type 1Receptors
Slide44
Slide45
Mitochondrial Dysfunction
Treatments
Planned Research

Lyme Disease Action, Registered Charity Number 1100448, Registered Company Number 4839410
Home | Terms and Conditions | Site map